Comparable to the 2020 resolution, Novartis AG’s $twenty five million 2016 civil resolution While using the SEC worried poor sponsorships of HCPs to conferences and inappropriate payments to HCPs to collect “health-related knowledge.” The fact that Novartis has become facing a considerably more substantial—and legal—resolution for similar